Docetaxel Injection, Solution
Product Images NDC 25021-245

Product Visual Gallery

This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Docetaxel (NDC 25021-245). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Sagent Pharmaceuticals, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Doc07 0005 01

Chemical structure of Docetaxel Anhydrous, showing the detailed molecular arrangement including multiple rings, hydroxyl groups, and ester functionalities characteristic of the docetaxel molecule.*

FDA Label Image

Doc07 0005 02

A line graph depicting disease-free survival (DFS) probability over time in months, with two curves labeled TAC and FAC. The y-axis shows DFS probability percentage, ranging from 0 to 100, and the x-axis shows time in months from 0 to 66. The graph compares DFS trends between TAC and FAC groups.*

FDA Label Image

Doc07 0005 03

A survival probability curve graph showing survival time in months on the x-axis and survival probability percentage on the y-axis. Two lines represent different treatment groups labeled as TAC and FAC, tracking survival probability trends over approximately 70 months.*

FDA Label Image

Doc07 0005 04

A Kaplan-Meier survival curve chart comparing overall survival probability over time in months between treatment groups labeled T75 and BSC. The vertical axis shows cumulative survival probability from 0 to 1.0, and the horizontal axis shows survival time in months from 0 to 21. A p-value of 0.010 for log-rank test is noted, indicating statistical difference between groups.*

FDA Label Image

Doc07 0005 05

A Kaplan-Meier survival curve comparing overall survival probabilities over time (in months) between two groups labeled T75 and V/I. The Y-axis shows cumulative survival probability from 0 to 1, and the X-axis shows survival time up to 21 months. A log-rank test p-value of 0.13 is noted on the chart.*

FDA Label Image

Doc07 0005 06

A Kaplan-Meier survival curve chart showing survival probability over time in months. The chart compares two groups labeled 'T75 q3w' (solid line) and 'M q3w' (dashed line), with survival probability on the vertical axis and survival time in months on the horizontal axis, up to 30 months.*

FDA Label Image

Doc07 0005 07

A line graph showing probability (%) over time (months) comparing two groups labeled TCF and CF. The y-axis represents probability from 0 to 100%, and the x-axis shows time up to 24 months. The TCF group has a generally higher probability over time than the CF group.*

FDA Label Image

Doc07 0005 08

A survival curve chart comparing survival probability (%) over time (months) between two groups labeled TCF and CF. The x-axis represents survival time in months up to 36 months, and the y-axis shows survival probability from 0% to 100%, with two declining lines indicating survival trends for each group.*

FDA Label Image

Doc07 0005 09

A line graph depicting progression-free survival (PFS) probability over time in months. Two survival curves are shown: a solid line for TPF and a dashed line for PF, illustrating changes in PFS probability up to 42 months.*

FDA Label Image

Doc07 0005 10

Kaplan-Meier survival curve comparing survival probability over time (in months) for two treatment groups labeled TPF and PF. The graph depicts declining survival probabilities up to 72 months, with TPF and PF represented by solid and dashed lines, respectively.*

FDA Label Image

Doc07 0005 11

A survival probability curve chart comparing two groups, TPF (n=255) and PF (n=246), over survival time in months. The Y-axis represents survival probability as a percentage, while the X-axis shows survival time from 0 to 72 months. The chart includes a table showing the number of patients at risk for each group at various time points along the X-axis.*

FDA Label Image

Doc07 0005 12

Label for Docetaxel Injection USP 20 mg/mL, a 1 mL single dose vial for intravenous infusion only. The label warns that it is a cytotoxic agent and notes the one-vial formulation contains 20 mg docetaxel per mL in a 50/50 (w/v) ratio with polysorbate 80 and dehydrated alcohol. It includes storage instructions, manufacturer Sagent Pharmaceuticals details, and a barcode with lot and expiration date fields.*

FDA Label Image

Doc07 0005 13

Label for Docetaxel Injection, USP, 80 mg per 4 mL (20 mg per mL) intravenous injection by Sagent Pharmaceuticals. It is a single dose vial with a cytotoxic agent warning and instructions for use, including storage conditions and disposal. The label includes manufacturer and barcode details.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.